Molecular glue as a new therapeutic strategy in metastatic KRAS-mutant lung cancer @gouthamnarla.bsky.social & team combined a PP2A molecular glue with RAS/MAPK inhibitors to restore tumor-suppressor activity & overcome drug resistance in mice with metastatic KRAS-driven NSCLC: buff.ly/1HzFVe5

Abstract B051: Discovery of SW-3431, a first-in-class molecular glue activator with potent and selective anti-tumor activity in PPP2R1A mutant cancers url: aacrjournals.org/mct/article/...

New publication from our group! We show that loss of carboxymethylation of protein phosphatase PP2A is a cellular response to MAPK pathway inhibition in NSCLC that leads to treatment resistance. Further- this resistance can be overcome with modulation of PP2A through small molecules...

What a time to have received a 9th percentile on my first MPI R01 as a new investigator...

I'm honored to have been awarded the Shields Family Research Grant for High-Grade Uterine Cancer from the Foundation for Women’s Cancer. This generous support will enable us to develop new models that more closely mimic the human disease, with the ultimate goal of benefiting patients. rb.gy/3qbh1k

Our new paper describing how mutations to the PP2A gene PPP2R1A drive high-grade uterine cancers is out now in this issue of Cancer Research by @theaacr.bsky.social aacrjournals.org/cancerres/ar...